Lisdexamfetamine (Vyvanse): Complete Clinical Guide for ADHD and BED

What Is Lisdexamfetamine and How Does It Work?

Lisdexamfetamine is a prodrug: it is pharmacologically inert until intestinal enzymes cleave the lysine carrier to release d-amphetamine. This enzymatic step is rate-limiting, so plasma d-amphetamine rises more gradually than it does after an equivalent dose of Adderall IR, and the peak concentration (Tmax) occurs roughly 3.8 hours post-dose rather than 1-3 hours. [1]

Once released, d-amphetamine enters the presynaptic terminal and reverses dopamine and norepinephrine transporters (DAT and NET), flooding the synapse with both catecholamines. Increased prefrontal dopamine sharpens working memory and impulse control; norepinephrine signaling tightens attentional focus via alpha-2A receptors on pyramidal neurons. [2] The brain does not distinguish between d-amphetamine derived from lisdexamfetamine and d-amphetamine from any other source, so the therapeutic effect is chemically identical to Adderall's active component. The difference lies entirely in delivery kinetics.

The prodrug design also means that crushing, snorting, or injecting lisdexamfetamine does not meaningfully accelerate the conversion step. A randomized human abuse-potential study (N=36) found that intravenous lisdexamfetamine produced significantly lower drug-liking scores than equimolar intravenous d-amphetamine, supporting its Schedule II rather than a higher immediate-abuse designation. [3]

FDA-Approved Indications and Off-Label Uses

The FDA granted lisdexamfetamine two distinct approvals. The first, in 2007, covered ADHD in children aged 6-12, later expanded to adolescents and adults. [4] The second, in 2015, covered moderate-to-severe BED in adults, making Vyvanse the only FDA-approved pharmacotherapy for that specific diagnosis at the time of its approval. [5]

Off-label, clinicians sometimes prescribe lisdexamfetamine for treatment-resistant depression as an adjunct, shift-work cognitive fatigue, and excessive daytime sleepiness not responsive to first-line agents, though evidence for these uses is less strong than the key ADHD and BED trial data. The American Academy of Child and Adolescent Psychiatry (AACAP) 2022 practice parameter states: "Stimulant medications are the first-line pharmacological treatment for ADHD across the lifespan, with evidence grades of 1 (highest) for both amphetamine and methylphenidate formulations." [6]

Lisdexamfetamine Dosing: ADHD and BED

For ADHD in children aged 6 and older and in adults, the recommended starting dose is 30 mg orally once every morning. The dose may be titrated in 10 mg or 20 mg increments at weekly intervals up to a maximum of 70 mg/day. [4] The capsule may be swallowed whole or opened and the contents dissolved in water, orange juice, or yogurt; the mixture must be consumed immediately. Chewable tablet formulations became available to simplify administration for younger patients.

For BED, the starting dose is 30 mg/day, titrated by 20 mg/week to a target of 50-70 mg/day. [5] Across the two key BED trials (SPD489-343 and SPD489-344, combined N=724), lisdexamfetamine at 50-70 mg/day reduced binge-eating days per week by 3.87 compared with 2.32 for placebo over 12 weeks (P<0.001). [7]

Patients with severe renal impairment (eGFR 15-30 mL/min/1.73 m²) should not exceed 50 mg/day, and those with end-stage renal disease should not exceed 30 mg/day, because the lysine metabolite accumulates when kidney clearance is reduced. [4]

Clinical Efficacy in ADHD: What the Trials Show

The key Phase III trial (SPD489-301, N=290, ages 6-12) showed that 30 mg, 50 mg, and 70 mg lisdexamfetamine all produced statistically significant reductions in ADHD Rating Scale IV (ADHD-RS-IV) total score versus placebo after 4 weeks, with effect sizes of 1.11, 1.21, and 1.32 respectively. [8] Effect sizes above 1.0 are considered large by Cohen's conventions, meaning lisdexamfetamine's signal surpasses most psychiatric pharmacotherapy.

In the adult ADHD program, a parallel placebo-controlled trial (N=420) demonstrated a 16.2-point reduction on the ADHD-RS-IV versus 9.4 points for placebo (P<0.001). [9] Notably, the time-to-effect advantage of lisdexamfetamine over immediate-release formulations is not speed of onset but the flatter concentration-time curve, which reduces late-morning rebound symptoms. [1]

A 2016 Cochrane systematic review of amphetamine formulations for adult ADHD (18 trials, N=2,521) confirmed that amphetamines produced a standardized mean difference of 0.79 on clinician-rated ADHD symptoms compared with placebo, placing them ahead of methylphenidate on head-to-head effect-size meta-analyses. [10]

How Lisdexamfetamine Compares to Other ADHD and Wakefulness Medications

Lisdexamfetamine vs. Mixed Amphetamine Salts (Adderall XR)

Adderall XR contains 75% d-amphetamine salts and 25% l-amphetamine salts in a dual-bead extended-release system, yielding two plasma peaks roughly 4 hours apart. Lisdexamfetamine produces a single smoother curve with a longer effective tail. [1] A 2013 double-blind crossover study (N=32) found that lisdexamfetamine and Adderall XR at equi-effective doses produced comparable ADHD symptom control, but lisdexamfetamine showed a lower subjective "drug-liking" score at 8 and 12 hours post-dose. [3] Both are Schedule II.

Adderall IR and Adderall XR have generic equivalents that are substantially cheaper; the 2023 entry of generic lisdexamfetamine dimesylate has narrowed but not eliminated the cost gap. [11]

Lisdexamfetamine vs. Methylphenidate (Ritalin, Concerta)

Methylphenidate works by blocking DAT and NET reuptake without triggering reverse transport, meaning it does not actively push dopamine into the synapse. This mechanism produces a smaller effect-size on ADHD-RS measures in direct comparative meta-analyses. The 2018 Lancet meta-analysis by Cortese et al. (133 double-blind RCTs, N=10,068 children) ranked amphetamines first for efficacy in children (standardized mean difference 0.78 vs. 0.56 for methylphenidate), a finding that influences prescribing patterns for patients with inadequate methylphenidate response. [12]

Concerta (osmotic-release methylphenidate) runs 8-12 hours versus lisdexamfetamine's 13-14 hours, which matters for adults with evening work demands or late-start school schedules. [4]

Lisdexamfetamine vs. Modafinil (Provigil) and Armodafinil (Nuvigil)

Modafinil and armodafinil are Schedule IV wakefulness-promoting agents approved for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea-related sleepiness. Neither is FDA-approved for ADHD, though off-label prescribing occurs. A 2000 randomized trial (N=248) found modafinil inferior to amphetamine for ADHD symptom reduction, and the FDA declined a pediatric ADHD NDA for modafinil in 2006 partly over serious rash concerns. [13] Clinicians sometimes choose modafinil when Schedule II concerns, cardiac contraindications, or patient preference disfavor amphetamine therapy. Abuse potential is meaningfully lower for modafinil (Schedule IV) than for lisdexamfetamine (Schedule II). [14]

Lisdexamfetamine vs. Non-Stimulants (Atomoxetine, Viloxazine)

Atomoxetine (Strattera) selectively inhibits NET without any dopamine action, producing a slower therapeutic onset of 4-6 weeks and a smaller effect size than stimulants. [12] The AACAP guideline designates non-stimulants as second-line agents when stimulant side effects are intolerable or when comorbid substance use disorder raises abuse concerns. [6] Viloxazine ER (Qelbree) received FDA approval in 2021 for ADHD in patients aged 6-17; adult data remain limited compared with lisdexamfetamine's strong Phase III package. [15]

Side Effects, Risks, and Contraindications

Lisdexamfetamine's most frequently reported adverse effects in Phase III trials were: decreased appetite (39%), dry mouth (26%), insomnia (20%), and increased heart rate (14%). [4] In the BED program, decreased appetite was reported by 46% of participants on 70 mg/day. [7]

Cardiovascular considerations are clinically meaningful. Lisdexamfetamine raises heart rate by a mean of 3.5 bpm and systolic blood pressure by 2-3 mmHg in adults. [4] The American Heart Association's 2008 scientific statement recommended an electrocardiogram before starting stimulant therapy in any patient with known or suspected cardiac disease. [16] Absolute contraindications include: advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, and use of monoamine oxidase inhibitors within 14 days. [4]

Growth velocity may slow in children during long-term stimulant therapy. A 3-year MTA study observation found that children on continuous stimulant treatment were on average 2 cm shorter and 2.7 kg lighter than non-medicated peers, though effects were modest at the individual level. [17] Many clinicians schedule brief "medication holidays" during school breaks to partially offset this effect, though evidence on whether holidays restore growth trajectory is mixed. [17]

Psychiatric side effects include new-onset or worsening psychosis, mania, and aggression, particularly in patients with a personal or family history of bipolar disorder. The FDA mandates a boxed warning noting that lisdexamfetamine has a high potential for abuse and that misuse may cause sudden death and serious cardiovascular adverse events. [4]

Serotonin syndrome is possible if lisdexamfetamine is combined with serotonergic agents; triptans, SSRIs at high doses, and tramadol all raise risk. [18]

Prescribing Considerations: Who Is a Candidate?

A comprehensive ADHD evaluation should include standardized rating scales (ADHD-RS, Conners 3, or CAARS for adults), a structured developmental history, and ruling out primary anxiety, mood disorders, and sleep disorders that can mimic ADHD. [6] Obtaining baseline blood pressure, heart rate, height, and weight before initiating lisdexamfetamine allows objective monitoring.

Patients with active substance use disorder (SUD) present a genuine clinical tension. Lisdexamfetamine's prodrug pharmacology offers some barrier to misuse, but Schedule II stimulants are still contraindicated in patients with active stimulant SUD in most prescribing guidelines. Atomoxetine or extended-release guanfacine (Intuniv) are preferred in that context. [6]

Pregnancy category is not formally assigned under current FDA labeling revisions, but lisdexamfetamine is listed as a risk-benefit decision drug; neonatal withdrawal, premature birth, and low birth weight have been observed in amphetamine-exposed pregnancies. [4] The Teratology Society and the Organization of Teratology Information Specialists advise case-by-case risk counseling rather than blanket discontinuation. [19]

Breastfeeding women should be aware that amphetamines distribute into breast milk at a milk-to-plasma ratio of roughly 2.8, delivering an estimated relative infant dose of 1.5-6.9% of the maternal weight-adjusted dose to a nursing infant. [20]

Monitoring Protocol After Initiation

At every follow-up visit, clinicians should record blood pressure, heart rate, weight, and height (in children), and reassess ADHD symptom burden with a validated scale. [6] The FDA label recommends evaluation approximately 4 weeks after each dose change and at 3-month intervals during stable therapy. [4]

Patients on lisdexamfetamine for BED should be monitored for emergence of cardiovascular symptoms, weight loss beyond clinical target, and any new psychiatric symptoms. Dose reductions or discontinuation may be required if systolic blood pressure rises above 140 mmHg or heart rate exceeds 100 bpm at rest persistently. [4]

Periodic electrocardiographic monitoring has no established mandatory frequency outside of patients with baseline cardiac risk, but a resting ECG annually is a reasonable clinical practice endorsed by several cardiology and psychiatry societies. [16]

Appetite suppression commonly reduces caloric intake enough to affect pediatric growth. Families can partially counter this by offering a nutrient-dense meal before the morning dose and a large caloric load in the evening when appetite partially returns. Referral to a registered dietitian for children with significant weight deceleration (>1 BMI percentile drop per year) is appropriate. [17]

Drug Interactions

Lisdexamfetamine's principal clinically significant interactions are as follows. Urinary alkalinizing agents (sodium bicarbonate, acetazolamide) increase tubular reabsorption of amphetamine, extending half-life and intensifying effects. Urinary acidifying agents (ammonium chloride, high-dose ascorbic acid) do the opposite, reducing serum levels. [4]

Concurrent use with SSRIs or SNRIs mildly elevates serotonergic tone; the combination is not absolutely contraindicated, but patients starting both should be counseled on early serotonin syndrome symptoms: agitation, myoclonus, diaphoresis, and hyperthermia. [18]

Beta-blockers blunt the tachycardic response but do not alter the CNS effects; they are sometimes added for patients with pronounced stimulant-related heart rate elevation who otherwise benefit from the drug. [4]

Generic Lisdexamfetamine: What Changed in 2023

The FDA approved the first generic lisdexamfetamine dimesylate capsules in 2023 following patent expiry. [11] Bioequivalence standards require the generic's 90% confidence interval for Cmax and AUC to fall within 80-125% of the reference listed drug. Because the conversion of lisdexamfetamine to d-amphetamine depends on intestinal enzymes rather than formulation-specific delivery technology, generic and brand-name lisdexamfetamine are pharmacokinetically interchangeable at the population level, though individual responses can vary. [11] Cash-pay prices dropped from roughly $380/month for brand Vyvanse to $80-120/month for the generic, significantly improving access. [11]